This guideline describes the biology of post-transplant lymphoproliferative disease (PTLD), pathological characteristics and their interpretation, pre-transplant screening and post-transplant surveillance. Risk factors and diagnostic strategies for PTLD are also included.

Declaration of Interests

The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.